标准,集群和急性过敏免疫疗法构建协议的比较
Michael C Lee1, Leah B Puglisi2, John M Kelso1
1Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, Calif.
概括
对过敏免疫疗法 (AIT) 的集群协议提供更快的维护剂量,类似于急诊协议,但不需要预处理,并具有相似的安全性. 这使得集群免疫疗法成为寻求更快缓解症状的患者的实用替代方案.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏学 过敏学
- 临床医学 临床医学
背景情况:
- 过敏免疫疗法 (AIT) 使用标准,集群或冲击剂量升级协议.
- 虽然集群和冲动协议加速达到维持剂量,但直接比较是有限的.
研究的目的:
- 为了比较标准,集群和急诊AIT协议之间的维护剂量和不良反应率的时间.
- 评估不同AIT剂量升级策略的有效性和安全性.
主要方法:
- 一项回顾性观察性研究分析了237名接受AIT的患者.
- 患者被分为标准,集群或急诊协议.
- 数据包括人口统计,维护时间,不良反应和AIT配方;急诊方案患者接受了额外的前期治疗.
主要成果:
- 冲击 (16.50周) 和集群 (19.33周) 协议的维持速度比标准协议 (31.09周) 快 (P < .001).
- 在集群和冲击协议之间没有发现维护时间的显著差异 (P = .322).
- 系统反应率在标准 (9.76%),集群 (9.84%) 和急诊 (14.86%) 协议中是相似的 (P = .526),尽管急诊协议的前期治疗.
结论:
- 集群AIT协议可以在与紧急协议相比的时间范围内实现维护剂量.
- 集群协议表现出类似的系统反应率,以加快协议,而不需要额外的预处理.
- 集群协议为加快AIT维护剂量提供了一种安全有效的替代方案.
相关概念视频
Allergic Reactions
27.8K
Overview
27.8K
Allergic Drug Reactions
898
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
898
Hypersensitivities
799
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
799
Cross-reactivity
31.3K
Overview
31.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357


